Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA9 | Q16790 | 6/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31291159 | 1.00 | CA12 (0.45) | CA12CA1CA2CA9TAAR1 | |
| SCHEMBL6767819 | 0.84 | AKR1B1 (0.46) | ALDH1A1NPC1RAB9A | |
| SCHEMBL11028284 | 0.83 | GABRA1 (0.40) | CA12CA1CA2CA9SIGMAR1 | |
| SCHEMBL1395809 | 0.83 | MAPK8 (0.50) | CA12CA1CA2CA9TAAR1 | |
| SCHEMBL1778391 | 0.82 | CA12 (0.47) | CA12CA1CA2CA9TAAR1 | |
| SCHEMBL1449282 | 0.82 | CA12 (0.47) | CA12CA1CA2CA9TAAR1 | |
| SCHEMBL4877644 | 0.80 | CA12 (0.33) | CA12CA1CA2CA9SIGMAR1 | |
| SCHEMBL6963978 | 0.80 | CA12 (0.46) | CA12CA1CA2CA9TAAR1 | |
| SCHEMBL286410 | 0.80 | AKR1B1 (0.61) | CA12CA1CA2CA9TAAR1 | |
| SCHEMBL30565097 | 0.80 | AKR1B1 (0.61) | CA12CA1CA2CA9TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756834-A | Synthesis method of 2- (aminocarbonylmethyl) phenylboronic acid pinacol ester | 大连双硼医药化工有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-111153865-A | Parecoxib sodium substituted impurity and preparation method thereof | 上海臣邦医药科技股份有限公司 | 2020-05-15 | — | — | CN | claimed |
| CN-120698931-A | Preparation method of oxcarbazepine | 河北科技大学 | 2025-09-26 | — | — | CN | disclosed |
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2025-05-29 | — | — | US | disclosed |
| CN-118974013-A | Pyrrolidine compounds | 伊莱利利公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-117756834-A | Synthesis method of 2- (aminocarbonylmethyl) phenylboronic acid pinacol ester | 大连双硼医药化工有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117756834-A | Synthesis method of 2- (aminocarbonylmethyl) phenylboronic acid pinacol ester | 大连双硼医药化工有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-3729190-B1 | ELECTROPHORETIC DISPLAY DEVICE AND ELECTRONIC APPARATUS | E INK CORP (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023178809-A1 | SYNTHESIS METHOD FOR NUCIFERINE OR DERIVATIVE THEREOF, NUCIFERINE DERIVATIVE AND APPLICATION THEREOF | 华侨大学 | 2023-09-28 | — | — | WO | disclosed |
| WO-2023146785-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11464783-B2 | Heterocyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-4873262-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, CARDIIOVASCULAR SYSTEM OR INTESTINAL TRACT | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-10 | — | — | US | disclosed |
| US-4851519-A | AMIDO NUCLEOSIDES, VIRICIDES | HOFFMANN-LA ROCHE INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4770810-A | Organic compound having a smectic phase A, and a mixture comprising this compound | THOMSON-CSF (FR) | 1988-09-13 | — | — | US | disclosed |
| EP-0257378-A1 | Pyrimidine derivatives, their preparation and medicaments containing these derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-03-02 | — | — | EP | disclosed |
| CN-87105758-A | Pyrimidine derivatives, their production and use | — | 1988-03-02 | — | — | CN | disclosed |
| US-4650799-A | Bis-dioxopiperazine derivatives, process for their preparation, antitumor agents comprising them and compositions containing them | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-03-17 | — | — | US | disclosed |
| EP-0140327-A2 | Bis-dioxopiperazine derivatives, process for their preparation, antitumor agents comprising them and compositions containing them | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-05-08 | — | — | EP | disclosed |
| US-4283532-A | Process for preparation of o-(2,6-dichloroanilino)phenylacetic acid and novel intermediate for use in preparation of the same | IKEDA MOHANDO CO., LTD. (JP) | 1981-08-11 | — | — | US | disclosed |
| US-3971828-A | METABOLISM, PROPHYLAXIS | SANTEN PHARMACEUTICAL CO. LTD. (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464783-B2 | Heterocyclic compounds | SLC10A1, CFTR, PKD1 | CA12 1227/4885CA1 2743/4885CA2 1635/4885 |
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | SDHA, GMPS, SDHB | CA12 3549/4885CA1 4534/4885CA2 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.